pazopanib
Selected indexed studies
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. (Lancet, 2012) [PMID:22595799]
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (N Engl J Med, 2013) [PMID:23964934]
- Drug review: Pazopanib. (Jpn J Clin Oncol, 2018) [PMID:29684209]
_Worker-drafted node — pending editorial review._
Connections
pazopanib is a side effect of
Sources
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. (2012) pubmed
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (2013) pubmed
- Drug review: Pazopanib. (2018) pubmed
- Pazopanib in ovarian cancer. (2015) pubmed
- Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. (2019) pubmed
- Pazopanib: a Review in Advanced Renal Cell Carcinoma. (2017) pubmed
- Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. (2018) pubmed
- Pazopanib: therapeutic developments. (2009) pubmed
- Pazopanib and antacids: insights from the WHO pharmacovigilance database. (2025) pubmed
- Pazopanib in sarcomas: expanding the PALETTE. (2013) pubmed